Search Results

Your search for Hagop Kantarjian, MD, and Robert Chapman, MD matches 2 pages

Showing 1 - 2

By Robert Manges, MD / March 25, 2016

340B Drug Pricing Program Revisited

I have to disagree with some of the conclusions drawn by Drs. Hagop Kantarjian and Robert Chapman in their editorial on the 340B Drug Pricing Program, which appeared in the January 25 issue of The ASCO Post. Although I’m sure I’m not the best person to provide an alternate view, I do feel strongly...

cost of care

By Hagop Kantarjian, MD, and Robert Chapman, MD / January 25, 2016

The 340B Drug Pricing Program: Background, Concerns, and Solutions

The 340B Drug Pricing Program was created by Congress through the Veterans Health Care Act of 1992 to allow some health-care entities—including safety-net providers with large shares of uninsured and low-income patients and other “covered entities”—to obtain drugs at discounted prices.1,2 Congress...

Apr

Today In Oncology

Search Results

Your search for Hagop Kantarjian, MD, and Robert Chapman, MD matches 2 pages

340B Drug Pricing Program Revisited

The 340B Drug Pricing Program: Background, Concerns, and Solutions

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer